Overview

Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
0
Participant gender:
All
Summary
Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia in this study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chulalongkorn University
Treatments:
Cyclophosphamide
Cyclosporine
Cyclosporins
Epoetin Alfa
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
Inclusion Criteria:

- Age more than 18 years old

- CKD patient with anti-r-huEpo associated PRCA

Exclusion Criteria:

- Pregnancy or lactating women

- Receiving immunosuppression

- Active infection

- Previous history of allergic reaction to cyclosporine, mycophenolate mofetil,
cyclophosphamide, prednisolone